Biopharmaceutical Company Secures Exclusive Global License For Alzheimer's Treatment

Silo Pharma, Inc. (Nasdaq: SILO), a developmental stage biopharmaceutical company, recently announced a major milestone in their mission to develop innovative treatments for neurological conditions. The company has secured an exclusive global license to further develop, manufacture, and commercialize its Alzheimer's drug, SPC-14. This announcement has generated considerable interest in the market, with Silo Pharma's stock surging by 64% in premarket trading, reaching $1.77 per share. $Silo Pharma (SILO.US)$